NCAM1 and breast carcinoma: Whatever the exact mechanism involved, our observations strongly suggest that CD56 expression on breast cancer cells enhances their susceptibility to NK-92 mediated cytotoxicity and therefore induction of its expression in CD56-negative cells might become a novel attractive approach for sensitizing initially resistant breast tumors.